Efficiency of different schemes of antihelicbacter therapy in patients with chronic gastroduodenal diseases and type 2 diabetes mellitus
- Authors: Fedorchenko Y.L1, Martynyuk M.V1
-
Affiliations:
- Far Eastern State Medical University of RMH
- Issue: No 2 (2018)
- Pages: 69-73
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/294580
- ID: 294580
Cite item
Open Access
Access granted
Abstract
Purpose. Evaluation of the effectiveness of different antihelicobacter therapy schemes for patients with chronic gastroduodenal di-seases (CGDD) in combination with type 2 diabetes mellitus (DM2). Material and Methods. An open comparative randomized study included 138 patients with CGDD and DM2. Patients were divided into 4 groups, depending on the type of scheme of eradication therapy of Helicobacter pylori. Results. The classical 10-day triple therapy (TT) has shown a lowest efficiency - 68.7%. Optimization of the TT scheme with the replacement of omeprazole by rabeprazole and prolongation of treatment up to 14 days made it possible to achieve 80.6% eradication of the pathogen. The addition of bismuth and probiotic preparations to the optimized TT scheme increased its efficiency to 94.1%. Additional appointment of metronidazole and probiotic within the optimized TT (enhanced combination therapy) allowed to achieve the best result of eradication - 97.2%. The regimens of treatment for Helicobacter pylori infection with addition of bismuth preparation and/or probiotic were found to be safe from the perspective of development of adverse effects. Conclusions. For patients with a combination of CGDD and DM2 infected with H. pylori, the most effective regimens of eradication therapy include enhanced optimized triple therapy (rabeprazole 20 mg twice a day, clarithromycin 1 g/day, amoxicillin 2 g/day) and enhanced combination therapy (rabeprazole 20 mg twice a day, clarithromycin 1 g/day, amoxicillin 2 g /day, metronidazole 1500 mg/day, S. boulardii 500 mg twice a day). These schemes proved to be the most effective from the standpoint of achieving clinical and endoscopic remission, and also the safest in terms of adverse effects arising during the eradication of H. pylori, in comparison with the classic regimens of treatment.
Full Text
About the authors
Yu. L Fedorchenko
Far Eastern State Medical University of RMH
Email: ulfedmed@mail.iu
Department of Faculty Therapy with the Course of Endocrinology
M. V Martynyuk
Far Eastern State Medical University of RMHDepartment of Faculty Therapy with the Course of Endocrinology
References
- Полуэктова Е.А., Ляшенко О.С., Шифрин О.С., Шептулин А.А. и др. Современные методы изучения микрофлоры желудочно-кишечного тракта человека. Рос. журн. гастроэнтерол., гепатол, колопроктол. 2017 2:85-91.
- Ивашкин В.Т., Маев И.В., Лапина Т.Л., Шептулин А.А. и др. Лечение инфекции Helicobacter pylori: мейстрим и новации. Рос. журн. гастро-энтерол, гепатол., колопроктол. 2017;4:4-21.
- Маев И.В., Самсонов А.А., Андреев Д.Н. Инфекция Helicobacter pylori. М., 2016.
- Дедов И.И., Сунцов Ю.И., Кудрякова С.В. Экономические проблемы сахарного диабета в России. Сахарный диабет. 2000;3:56-8.
- Gasbarrini A., Ojetti V., Pitocco D., Armuzzi A., Silveri N.G., Pola P., Ghirlanda G., Gasbarrini G. Efficacy of different Helicobacter pylori eradication regimens in patients affected by insulin-dependent diabetes mellitus. Scand. J. Gastroenterol. 2000;35:260-63.
- Мкртумян А.М., Казюлин А.Н., Баирова К.И. Частота и степень инфицированности хели-кобактером при сахарном диабете 2 типа. Сахарныйдиабет. 2010;1:77-9.
- Филиппов Ю. Гастроэнтерологические нарушения при диабетической нейропатии. Врач. 2011;4:96-101.
- Apfel S.C., Asbury А.К., Bill V., et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J. Neurol. Sci. 2001;189(1-2):3-5.
- Malfertheiner P., Megraud F., O'Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., Bazzoli F., Gasbarrini A., Atherton J., Graham D.Y., Hunt R., Moayyedi P., Rokkas T., Rugge M., Selgrad M., Suerbaum S., Sugano K., El-Omar E.M. Management of Helicobacter pylori infection -the Maastricht V/ Florence Consensus Report. Gut. 2017;66:6-30.
- Georgopolos S.D., Papastergiou V., Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: A paradigm shift to improved efficacy. Gastroenterol. Res. Pract. 2012. Article ID 757926.
- Симаненков С.В., Захарова Н.И., Савилова И.В. Сравнительное исследование препаратов Денол и Новобисмол в схемах эрадикации у пациентов с Н. pylori-ассоциированными заболеваниями. Эксперимент, и клин. гастроэнтерология. 2015;1:66-71.
- Delchier J.C., Ebert M., Maltfertheiner P Helicobacter pylori in gastric lymphoma and carcinoma. Current Opinion in Gastroenterology: The year in Helicobacter pylori. 1998; 14(1):41-5.
- Mehmet S., Uygur-Bayramicli O., Haluk S. Type 2 diabetes mellitus affects eradication rate of Helicobacter pylori. World. J. Gastroenterol. 2003;9(5):1126-28.
- Wiklund I., Bardhan K.D., Muller-Lissner S., Bigard M.A., Bianchi Porro G., Ponce J., Hosie J., Scott M., Weir D., Fulton C., Gillon K., Peacock R. Quality of life during acute and intermittent of gastroesophageal reflux disease with omeprazol compared with ranitidine. Results from a multicentre clinical trial. The European Study Group. Ital. J. Gastroenterol. Hepatol. 1998;30(1):19-27.
- Новик А.А., Ионова Т.И. Руководство по исследованию качества жизни в медицине (3-е изд.) / Под ред. Ю.Л. Шевченко. М., 2012.
- Dore M.P., Lu H., Graham D.Y. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870-78.
- Cindoruk M., Erkan G., Karakan T., Dursun A., Unal S. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double blind stude. Helicobacter. 2007;12(4):309-16.
Supplementary files
